DoW Breast Cancer, Transformative Breast Cancer Consortium Award | HT942526BCRPTBCCA

FY26 BCRP Transformative Breast Cancer Consortium Award (HT942526BCRPTBCCA) FAQs

1) What is the FY26 BCRP Transformative Breast Cancer Consortium Award?

It is a Department of the Army (USAMRAA) funding opportunity under the FY26 Breast Cancer Research Program (BCRP) designed to support large, tightly coordinated research consortia focused on achieving transformative advances in breast cancer research and outcomes.

2) What is the main goal of this award?

The purpose is to back collaborations and ideas that can meaningfully change outcomes for people living with breast cancer, as well as individuals at elevated risk, and to accelerate progress toward the long-term goal of ending breast cancer.

3) What kinds of research efforts is this mechanism intended for?

This mechanism is intended for problems that are too complex or far-reaching for a single lab, a single investigator, or even a typical multi-investigator team. The program is designed for large-scale efforts that require deep integration across multiple projects, disciplines, and institutions.

4) What does the program mean by a "transformative" impact?

Based on the opportunity description, "transformative" implies ambitious goals, strong integration across the consortium's projects, and clear potential to substantially change the field or clinical practice, rather than producing incremental progress.

5) What is expected of the consortium structure and how integrated does it need to be?

The opportunity expects a synergistic, highly integrated, multidisciplinary, and multi-institutional consortium. In practice, the funded effort should operate like a coordinated program, not a set of loosely related projects.

6) Are multiple institutions required or just encouraged?

The program emphasizes a multi-institutional consortium model and expects applicants to bring together leading scientists and clinicians across institutions and specialties, indicating that multi-institutional participation is a core expectation of the mechanism.

7) Are clinicians and scientists both expected to be involved?

Yes. The description highlights bringing together leading scientists and clinicians across institutions and specialties as part of a multidisciplinary approach.

8) Are breast cancer consumer advocates required?

Yes. The consortium is expected to include breast cancer consumer advocates as active participants, and each project team must include at least one breast cancer consumer advocate.

9) What does it mean for consumer advocates to be "active participants"?

The opportunity states that consumer advocates should be embedded throughout the consortium rather than added at the end, suggesting they should be integrated into the work of each project team and the overall consortium effort.

10) How many Principal Investigators (PIs) can be included?

The award allows up to five Principal Investigators in total. This group includes a Consortium Director plus three or four Project Team PIs.

11) Who submits the pre-application?

Only the Consortium Director submits the pre-application.

12) Who must submit components at the full application stage?

At the full application stage, all associated PIs must submit their required application components. This includes the Consortium Director and each Project Team PI.

13) What happens if a linked PI does not submit their required components by the full application deadline?

The notice states that missing submissions from any of the linked PIs by the full application deadline can trigger administrative withdrawal. This makes coordination across the full PI leadership team a key compliance requirement.

14) Do applications have to address specific program priorities?

Yes. Applications must align with at least one of the FY26 BCRP overarching challenges.

15) What if our consortium wants to tackle a fundamental issue that is not one of the stated overarching challenges?

If a consortium proposes a different fundamental issue, it must either provide a compelling justification for why an exception is warranted or explicitly connect that issue to at least one of the overarching challenges.

16) What is the funding instrument for this opportunity?

The opportunity uses a Cooperative Agreement funding instrument.

17) What does a Cooperative Agreement imply compared to a standard grant?

The description notes that a Cooperative Agreement typically indicates substantial federal involvement during project performance compared with a standard grant.

18) What agency is offering this opportunity?

The agency is the Department of the Army, administered through USAMRAA.

19) What is the opportunity number and CFDA listing?

The opportunity number is HT942526BCRPTBCCA, and the CFDA listing is 12.420.

20) What is the eligibility for this funding opportunity?

Eligibility is described as unrestricted in the provided information.

21) What is the application deadline?

The original closing date listed is September 30, 2026.

22) How many awards are expected to be made?

The posting indicates an expectation of one award.

23) Is there an award ceiling (maximum funding amount) specified?

An award ceiling is not specified in the provided source text.

24) Why is tight coordination and synergy emphasized so strongly?

The program is built for complex, far-reaching challenges that cannot be solved by a single lab or a conventional multi-investigator arrangement. The expectation is that the consortium will function as a unified, coordinated program capable of delivering a field-changing outcome.

25) What is the practical leadership model implied by the PI structure?

The structure implies a single Consortium Director coordinating three or four major project components led by Project Team PIs, with the intent that these components run in parallel under one integrated strategy.